GlassScriptPhysician profile
Rebecca Brett
NPI 1649240037
$697.15
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41.23 · 2020: $173 · 2021: $378 · 2022: $105.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $176.62 | 2019-2022 | |
| Lilly USA, LLC | $101.60 | 2020-2022 | |
| Abbvie INC. | $86.68 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $42.37 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $37.63 | 2021 | |
| Pfizer INC. | $36.58 | 2021 | |
| Janssen Pharmaceuticals, INC | $35.52 | 2021 | |
| Dexcom, INC. | $21.16 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.42 | 2022 | |
| Boston Scientific Corporation | $19.84 | 2021 | |
| Abbott Laboratories | $19.78 | 2022 | |
| Arbor Pharmaceuticals, INC. | $19.27 | 2021 | |
| Global Blood Therapeutics, INC. | $19.22 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $18.53 | 2020 | |
| Allergan, INC. | $14.92 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $14.66 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.35 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebecca Brett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.